• Corpus ID: 22102314

Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.

@article{Mohammad1998SuccessfulTO,
  title={Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.},
  author={Ramzi M. Mohammad and Mary L. Varterasian and V P Almatchy and Ghadeer N. Hannoudi and George R. Pettit and Ayad Al-Katib},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1998},
  volume={4 5},
  pages={
          1337-43
        }
}
  • R. Mohammad, M. Varterasian, +3 authors A. Al-Katib
  • Published 1 May 1998
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
We tested the activity of dolastatin 10 (a natural product derived from the shell-less marine mollusk, Dolabella auricularia, a sea hare) and its structural modification, auristatin PE, alone and in combination with bryostatin 1 (a protein kinase C activator derived from the marine bryozoan Bugula neritina) on a human B-cell chronic lymphocytic leukemia cell line (WSU-CLL) and in a severe combined immune deficient (SCID) mouse xenograft model bearing this cell line. WSU-CLL cells were cultured… 
Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog.
TLDR
Examination of the effects of CD437 and a nonretinoidal analog (MM002) on the in vitro proliferation of the ALL-REH cell line and in vitro and in vivo growth of a novel Epstein-Barr virus-negative (EBV(-)) B-cell chronic lymphocytic leukemia cell line suggest that these analogs may have a potential role in the treatment of B-CLL and ALL.
Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug.
  • Philip, Zonder
  • Medicine
    Expert opinion on investigational drugs
  • 1999
TLDR
There is ample in vitro data demonstrating that bryo 1 can sensitise tumour cells to cytotoxic agents, and recent clinical work has focused on combining b Bryo 1 with traditional chemotherapeutic agents for both haematologic and non-haematological cancers.
New Drugs for the Treament of Chronic Lymphocytic Leukemia
TLDR
Compound GW506U78, the prodrug for arabinosylguanine, is an interesting new purine analog, which induces responses in about one-third of patients with relapsed or refractory CLL, and agents in clinical development include retinoids and arsenicals which induce apoptosis, farnesyl transferase inhibitors, proteasome inhibitors and the signal transduction modulators.
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
TLDR
Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent in patients with hormone-refractory prostate cancer.
Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma 1
Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstratedin vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II
Marine natural products: Bryostatins in preclinical and clinical studies
TLDR
Bryostatin's anticancer activity has been proved against various cancer types and their significant antineoplastic activity against several tumor types has also been established and described.
Bryostatin-1: A Novel PKC Inhibitor in Clinical Development
TLDR
Bryostatin-1 is a macrocyclic lactone derived from a marine invertebrate that binds to the regulatory domain of protein kinase C that inhibits proliferation, induces differentiation, and promotes apoptosis in numerous hematological and solid tumor cell lines.
Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells.
TLDR
These findings suggest that these cytotoxic effects of novel bile acid derivatives on human breast carcinoma cells were mediated via apoptosis through a p53-independent pathway.
Preclinical and clinical studies on bryostatins, a class of marine-derived protein kinase C modulators: A mini-review.
TLDR
Bryostatin-1 has shown acceptable IV pharmacokinetic profile in mice and displayed promising in-vivo efficacy in mice models of various cancers and Alzheimer's disease, and provided encouraging results in combination with other chemotherapy agents.
Progress in the development and acquisition of anticancer agents from marine sources.
TLDR
Some of the technical strategies that are being employed to collect and identify novel marine products with potential antitumoral properties are reviewed, and a summary of the available clinical trial information of agents with promising activity is provided.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
TLDR
The results suggest that the exposure of WSU-DLCL2 cells to Bryo1 prior to treatment with VCR enhances apoptosis, a phenomenon which might be exploited for future therapies.
Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.
TLDR
The results indicate that Bryo1 shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high- grade SCNCL and has a potential therapeutic role as a B-cell differentiating agent.
Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
TLDR
It is recommended that Bryo1 be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease.
Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
TLDR
The ability of bryostatin 1 to inhibit the in vitro growth and in vivo development of a panel of four murine tumors of diverse tissue origins and the observation that five of a Panel of six human B-cell lymphoma cell lines were sensitive to the growth inhibitory effects of bRYostatin in vitro suggest that brystatin may be effective in treating lymphoid malignancies in humans.
Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay
TLDR
The history of antitumor drug discovery has essentially been the use of two lymphocytic leukemias of mice as selection funnels through which all agents needed to pass in order to advance toward clinical development, and it is thus not surprising that agents in the clinic are highly active against these tumor systems.
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
TLDR
Preliminary studies indicated that dolastatin 10, like vinblastine, causes formation of a cold-stable tubulin aggregate at higher drug concentrations, and it was confirmed that rhizoxin, phomopsin A, and maytansine also inhibit the binding of radiolabeled vin Blastine and vincristine to tubulin.
Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.
TLDR
The results suggest that bryostatin 1 activates HL-60 cell protein kinase C and that this effect is associated with induction of monocytic differentiation.
Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.
TLDR
The cell line and the xenograft described can be used as a model to facilitate the development of new therapeutic agents against CLL in man to test the efficacy of selected standard chemotherapy drugs and new therapeutic agent against WSU-CLL.
Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy.
  • S. Grant, W. Jarvis
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
TLDR
Although several of the principles established during this period continue to serve as guidelines for the development of modern chemotherapeutic regimens, it is uncertain whether this general strategy will prove superior to the more empirical approaches that preceded it.
Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression
TLDR
It is reported here that IL-4 protects the B-CLL cells from death by apoptosis (programmed cell death [PCD]), and it is proposed thatIL-4 has an essential role in the pathogenesis of CLL disease, by preventing both the death and the proliferation of the malignant B cells.
...
1
2
3
...